The European Alliance for Clinical Trials (EACH) has published a position paper on April 13, 2026, proposing reforms to the supervisory and reporting framework for the Medical Information Sharing Platform (MISP). The paper calls for streamlined oversight mechanisms and standardized reporting templates to reduce administrative burden on sponsors and researchers.
This proposal follows a series of recent EMA initiatives aimed at improving clinical trial processes. On April 9, 2026, EMA published an updated FAQ for the Clinical Trial Information System (CTIS) and proposed a template for sharing documents to support regulatory reliance. Earlier, on April 7, 2026, EMA released a new training module for CTIS covering substantial modifications to ongoing trials, and the Pharmacovigilance Risk Assessment Committee (PRAC) mandated new safety wording for pharmaceutical products.
EACH's position paper addresses concerns about the complexity of current supervisory requirements, which the alliance argues can delay trial initiation and increase costs. The proposed reforms aim to enhance efficiency while maintaining patient safety and data integrity. The paper also emphasizes the need for harmonized reporting standards across member states to facilitate multi-country trials.
The impact of these proposals would be significant for several stakeholders. For pharmaceutical companies and contract research organizations, streamlined reporting could reduce compliance costs and accelerate time-to-market for new therapies. However, national regulatory authorities may face challenges in adapting to new standardized procedures, potentially requiring additional training and resources. Academic researchers could benefit from simplified processes, but may need to adjust to new reporting templates. Patient advocacy groups may welcome improved transparency, but could be concerned that reduced oversight might compromise safety monitoring. Overall, the reforms represent a trade-off between operational efficiency and regulatory rigor.